GLP-1 peptide therapeutics have become a proving ground for modern analytical science. These molecules sit between traditional small molecules and large biologics, which makes them harder to characterize and harder to control across development. As demand grows, laboratories need workflows that deliver structural insight, trace-level sensitivity, and continuity from early development through manufacturing.
In a recent episode of Concentrating on Chromatography, produced in collaboration with Separation Science, David Oliva spoke with Kelly Broster, Senior Manager of Pharma & Biopharma Market Development and Collaborations at Thermo Fisher Scientific, to discuss the latest GLP-1 workflows.
Why GLP-1 Peptides Challenge Analytical Workflows
Peptide drugs such as semaglutide bring more complexity than many small molecule drugs. They are larger, more structurally dynamic, and often chemically modified to improve stability, half-life, or absorption. They can also contain subtle sequence variants, post-translational modifications, and low-level impurities that complicate characterization.
That complexity raises the analytical bar. Small changes can affect receptor binding, potency, stability, or immunogenicity. Developers therefore need methods that can resolve closely related species and confirm structural identity with confidence.
Why LC-MS Remains Central
For GLP-1 peptide analysis, chromatography and mass spectrometry work best together. Chromatography helps separate complex mixtures and reduce interference. High-resolution accurate mass spectrometry then adds molecular specificity, structural confirmation, and the ability to detect low-abundance variants.
This combination gives scientists a stronger view of co-eluting species, trace impurities, and modification patterns. It also supports the detailed characterization required for regulatory submissions and product quality assessments.
Sensitivity Matters Early
Sensitivity plays a direct role in peptide drug safety. Trace impurities and very low-level variants can have an outsized effect on final product quality, so developers need to detect them early, before scale-up increases risk.
High-resolution mass spectrometry helps meet that need by supporting impurity detection at very low levels, even in challenging matrices. That gives teams a better chance to identify risks sooner and maintain tighter control as development progresses.
Continuity Across Development Stages
One of the clearest themes in this discussion is workflow continuity. Developers cannot afford to rebuild analytical methods at every stage of development. Instead, workflows need to move from research to QC to manufacturing without losing reproducibility, data integrity, or scalability.
That puts pressure on the full analytical ecosystem. Instruments, consumables, software, and data platforms all need to support robust method transfer and harmonized operations across sites.
What Comes Next for Biopharma Analysis
The lessons from GLP-1 peptides extend well beyond one therapeutic class. As drug modalities grow more complex, developers will need deeper molecular insight, earlier risk detection, and stronger analytical control across the full product lifecycle.
That shift will likely bring more automation, greater use of advanced informatics, and more AI-assisted interpretation. Even so, the foundation will stay the same: high-quality analytical data generated through robust, high-resolution workflows.
Learn More:
- Explore the Concentrating On Chromatography podcast to dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva.
Connect with Kelly:
- LinkedIn: Kelly Broster (McMahon)
